Freenome获得2.54亿美元战略投资
Freenome是一个液体活检诊断平台,可用无细胞DNA测序做癌症筛查。近日,Freenome宣布获得新投资者和现有投资者追加的2.54亿美元融资。Roche罗氏领投最新轮融资,a16z Life Sciences Growth Fund、美国癌症协会的BrightEdge Ventures、ARK Investments、ArrowMark Partners、Artis Ventures、贝恩资本生命科学、Cormorant Capital、DCVC、Eventide Asset Management LLC、Intermountain Ventures、Perceptive Advisors、Polaris Partners、Pura Vida Investments、Quest Diagnostics(NYSE:DGX)、RA Capital Management、,Sands Capital,Section 32,Squarepoint Capital,T. Rowe Price Associates, Inc.等跟投。(IT桔子)
Copyright © DoNews 2000-2025 All Rights Reserved
蜀ICP备2024059877号-1